Voyager Therapeutics upgraded to Outperform from Neutral at Wedbush. As previously reported, Wedbush analyst David Nierengarten upgraded Voyager Therapeutics to Outperform from Neutral, but lowered his price target on shares to $28 from $29. The analyst cited valuation, after a sell-off in the stock over the last two months cut the share price nearly in half, including a large dip in the stock on Thursday due to confusing hedging language in Voyager’s 10Q filing. Nierengarten said the risk/reward is now more favorable at these levels ahead of the company’s pivotal trial start for VY-AADC.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.